What is it about?
In-silico anti-viral activity of Hydroxychloroquine (HCQ) and its Hyaluronic Acid-derivative (HA-HCQ) towards different SARS-CoV-2 protein molecular targets were studied. Four different SARS-CoV-2 proteins molecular target i.e., three different main proteases and one helicase were chosen for In-silico anti-viral analysis. The present study suggested that further in-vitro and in-vivo examination of HA-HCQ drug conjugate will be useful to establish a promising early stage antiviral drug for the novel treatment of COVID-19.
Featured Image
Why is it important?
To propose a novel and efficient drug for COVID-19 disease, using an old and well-known antiviral drug, Hydroxychloroquine (HCQ), covalently linking it at a specific position with the Hyaluronic acid (HA) to afford HA-HCQ conjugate to increase its bioavailability, safe, improve its localization, controlled release in the body, enhance its overall efficiency, and eliminate or reduce HCQ’s systemic toxicity
Perspectives
To develop a drug conjugate, HA-HCQ from hyaluronic acid (HA) biomaterial, which is present in extracellular matrices and the synovial fluid of joints, and HCQ, to increase its bioavailability, stability, localization, controlled release, enhance the efficacy and safety, and devoid of any side effects.
Professor Aroulmoji Vincent
Mahendra Educational Trust
Read the Original
This page is a summary of: Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins, Journal of Molecular Structure, August 2021, Elsevier,
DOI: 10.1016/j.molstruc.2021.130457.
You can read the full text:
Contributors
The following have contributed to this page
